B-苄基-9-硼杂双环[3.3.1]壬烷 | 53317-09-2

• 物质功能分类: 化学试剂 - 有机试剂 - 硼烷
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 金属杂环化合物
• 中文名称: B-苄基-9-硼杂双环[3.3.1]壬烷
• 中文别名: B-苯甲基-9-BBN；B-苄基-9-BBN
• 英文名称: 9-benzyl-9-borabicyclo[3.3.1]nonane
• 英文别名: B-benzyl-9-borabicyclo[3.3.1]nonane；B-benzyl-9-BBN
• CAS: 53317-09-2
• 化学式: C₁₅H₂₁B
• mdl: MFCD23701662
• 分子量: 212.143
• InChiKey: IQRBNRFCRAJXJF-UHFFFAOYSA-N

物化性质

• 沸点：
  67 °C
• 密度：
  0.906 g/mL at 25 °C
• 闪点：
  −2 °F
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  5.23
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 危险品标志：
  F,Xi
• 安全说明：
  S16,S29,S33
• 危险类别码：
  R19,R11,R36/37
• 海关编码：
  2902909090
• 危险标志：
  GHS02,GHS07,GHS08
• 危险品运输编号：
  UN 1993
• 危险性描述：
  H225,H261,H302,H319,H335,H351
• 危险性防范说明：
  P210,P231 + P232,P280,P370 + P378,P402 + P404,P403 + P235
• 储存条件：
  将贮藏器密封后，放入一个紧密的容器中，并存放在阴凉、干燥的地方。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : B-Benzyl-9-BBN solution
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Flammable liquids (Category 2), H225
Substances and mixtures, which in contact with water, emit flammable gases (Category 2), H261
Eye irritation (Category 2), H319
Carcinogenicity (Category 2), H351
Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
F Highly flammable R11
Xn Harmful R40
Xi Irritant R36/37
R19, R14
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H225 Highly flammable liquid and vapour.
H261 In contact with water releases flammable gases.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H351 Suspected of causing cancer.
Precautionary statement(s)
P210 Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P231 + P232 Handle under inert gas. Protect from moisture.
P261 Avoid breathing vapours.
P281 Use personal protective equipment as required.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
P422 Store contents under inert gas.
Supplemental Hazard information (EU)
EUH014 Reacts violently with water.
EUH019 May form explosive peroxides.
According to European Directive 67/548/EEC as amended.
Hazard symbol(s) F Highly flammable
Xn Harmful
R-phrase(s)
R11 Highly flammable.
R14 Reacts violently with water.
R19 May form explosive peroxides.
R36/37 Irritating to eyes and respiratory system.
R40 Limited evidence of a carcinogenic effect.
S-phrase(s)
S16 Keep away from sources of ignition - No smoking.
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36/37 Wear suitable protective clothing and gloves.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Mixtures
Formula : C15H21B
Molecular Weight : 212,14 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
Tetrahydrofuran
CAS-No. 109-99-9 Flam. Liq. 2; Eye Irrit. 2; Carc. <= 100 %
EC-No. 203-726-8 2; STOT SE 3; H225, H319,
Index-No. 603-025-00-0 H335, H351, EUH019
Registration number 01-2119444314-46-XXXX
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
Tetrahydrofuran
CAS-No. 109-99-9 F, Xn, Carc.Cat.3, R11 - R19 - <= 100 %
EC-No. 203-726-8 R40 - R36/37
Index-No. 603-025-00-0
Registration number 01-2119444314-46-XXXX
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with
water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Dry powder
Special hazards arising from the substance or mixture
no data available
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.
Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to
form explosive concentrations. Vapours can accumulate in low areas.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and
place in container for disposal according to local regulations (see section 13). Do not flush with water.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic
charge.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Never allow product to get in contact with water during storage.
Store under inert gas. Dry residue is explosive. Air sensitive.
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, Flame retardant antistatic protective clothing, The type
of protective equipment must be selected according to the concentration and amount of the
dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type AXBEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 65,0 - 67,0 °C
boiling range
g) Flash point -17 °C - closed cup
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower Upper explosion limit: 11,8 %(V)
flammability or Lower explosion limit: 1,8 %(V)
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 0,906 g/cm3 at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
Reacts violently with water.
Conditions to avoid
Heat, flames and sparks. Extremes of temperature and direct sunlight. Exposure to moisture.
Incompatible materials
Oxidizing agents, Oxygen
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
Central nervous system depression, Cough, chest pain, Difficulty in breathing, Exposure to high airborne
concentrations can cause anesthetic effects., To the best of our knowledge, the chemical, physical, and
toxicological properties have not been thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting
as this material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal
company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2924 IMDG: 2924 IATA: 2924
UN proper shipping name
ADR/RID: FLAMMABLE LIQUID, CORROSIVE, N.O.S.
IMDG: FLAMMABLE LIQUID, CORROSIVE, N.O.S.
IATA: Flammable liquid, corrosive, n.o.s.
Transport hazard class(es)
ADR/RID: 3 (8) IMDG: 3 (8) IATA: 3 (8)
Packaging group
ADR/RID: II IMDG: II IATA: II
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  B-苄基-9-硼杂双环[3.3.1]壬烷 在 盐酸 、 四(三苯基膦)钯 、 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 12.0h， 生成 (4-(5-benzylpyrimidin-2-yl)piperazin-1-yl)(4-((quinazolin-4-ylamino)methyl)phenyl)methanone
  参考文献：
  名称：

  Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives

  摘要：

  Protein kinases play several pertinent roles in cell proliferation, and targeting these proteins has been shown to be a successful strategy toward controlling different malignancies. Despite the great discovery stories during the last two decades, there is still a demand for anticancer small molecules with the potential of being selective on both the protein kinase and/or the cellular level. A series of novel piperazinylpyrimidine compounds were synthesized and tested for their potential to selectively inhibit the growth of certain tumor cell lines included within the NCI-60 cell line panel. MDA-MB-468, a triple-negative/basal-like breast carcinoma, cell line was among the most sensitive cell lines towards compounds 4 and 15. The three most interesting compounds identified in cellular screens (4, 15, and 16) were subjected to kinase profiling and found to have an interesting selective tendency to target certain kinase subfamily members; PDGFR, CK1, RAF and others. Compound 4 showed a selective tendency to bind to and/or inhibit the function of certain KIT and PDGFRA mutants compared to their wild-type isoforms. Piperazinylpyrimidine based derivatives represent a new class of selective kinase inhibitors. Significantly 4 is more potent at inhibiting oncogenic mutant forms of PDGFR family kinases, which is relevant in terms of its potential use in treating tumors that have become resistant to treatment or driven by such mutations. The clinical demand for agents useful in the control of triple-negative/basal-like breast cancer justifies our interest in compound 15 which is a potent growth inhibitor of MDA-MB-468 cell line. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.02.057
• 作为产物：
  描述：

  1-(苄基磺酰基)-3-氟苯 在 正丁基锂 、 potassium peroxomonosulfate 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 水 为溶剂， 反应 12.5h， 生成 B-苄基-9-硼杂双环[3.3.1]壬烷
  参考文献：
  名称：

  从醇的合成米-Fluorophenylsulfones和Dialkylboranes：应用E7389的C14-C35大厦

  摘要：

  的反应米-fluorophenylsulfone阴离子与dialkylboranes，随后碱性过氧化氢的氧化，以高收率收率醇。据报道，该方法的工艺，范围和局限性得到优化，并被用于合成E7389的一种C14–C35构建基块，这是葫芦素B的右半类似物。

  DOI：

  10.1021/ol300672q

文献信息

• Mild Synthesis of Organophosphorus Compounds:  Reaction of Phosphorus-Containing Carbenoids with Organoboranes
  作者：Monika I. Antczak、Jean-Luc Montchamp

  DOI：10.1021/ol800085u

  日期：2008.3.1

  Organoboranes react with phosphorus-containing carbenoids to produce a variety of functionalized organophosphorus compounds under mild conditions. In some cases, selective migration of one group attached to boron can be observed. Phosphonite-borane complexes are introduced as novel synthons for the synthesis of phosphinic esters.

  有机硼烷在温和条件下与含磷类卡宾反应生成多种功能化的有机磷化合物。在某些情况下，可以观察到与硼相连的一组选择性迁移。次膦酸酯-硼烷复合物被引入作为合成次膦酸酯的新型合成子。
• [EN] 6 - ALKYNYL PYRIDINES AS SMAC MIMETICS<br/>[FR] 6-ALCYNYLE PYRIDINES UTILISÉES COMME MIMÉTIQUES DE SMAC
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013127729A1

  公开（公告）日：2013-09-06

  This invention relates to 6-alkynyl-pyridines of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R5 have the meanings given in the claims and in the specification.

  这项发明涉及一般式(I)的6-炔基吡啶，它们作为SMAC模拟物的用途，含有它们的药物组合物，以及它们作为治疗和/或预防由细胞过度或异常增殖引起的疾病及相关症状（如癌症）的药物的用途。基团R1到R5的含义如索赔和说明书中所述。
• 5-Alkynyl Pyridine
  申请人：REISER Ulrich

  公开号：US20130225567A1

  公开（公告）日：2013-08-29

  5-alkynyl-pyridine of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R 1 to R 5 have the meanings given in the claims and in the specification.

  通用式（I）的5-炔基吡啶 它们作为SMAC模拟物的用途，含有它们的药物组合物，以及它们作为治疗和/或预防由细胞过度或异常增殖引起的疾病及相关症状（如癌症）的药物的用途。 R组 1 至R组 5 的含义如索赔和说明书中所述。
• [EN] QUINOLINE DERIVATIVES AND THEIR USES FOR RHINITIS AND URTICARIA<br/>[FR] DÉRIVÉS DE QUINOLINE ET APPLICATIONS ASSOCIÉES DANS LA RHINITE ET L'URTICAIRE
  申请人：GLAXO GROUP LTD

  公开号：WO2010094643A1

  公开（公告）日：2010-08-26

  The present invention relates to compounds of formula (I) and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various diseases, such as allergic rhinitis.

  本发明涉及式(I)的化合物及其盐，其制备方法，含有它们的组合物，以及它们在治疗各种疾病（如过敏性鼻炎）中的用途。
• NOVEL COMPOUNDS
  申请人：FARNABY William

  公开号：US20130052281A1

  公开（公告）日：2013-02-28

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）的化合物及其药用盐，其中R1和R2如规范中定义，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的用途。